Global Hereditary Angioedema Therapeutics Market - 2023-2030

Market Overview

The Global Hereditary Angioedema Therapeutics Market reached US$ 2.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.4 billion by 2030. The global hereditary angioedema therapeutics market is expected to exhibit a CAGR 8.6% during the forecast period (2023-2030). The growing adoption of prophylactic therapies, focus on patient-centric approaches, and introduction of novel therapies are some recent market trends.

The global hereditary angioedema therapeutics market has been expanding continuously in recent years. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling episodes in different parts of the body. HAE is caused by mutations in the SERPING1 gene, which encodes for the blood protein C1-inhibitor and controls a series of processes that result in inflammation and blood clotting.

The global hereditary angioedema therapeutics market scope comprises components encompassing drug class such as kallikrein inhibitor, c1 esterase inhibitor, and selective bradykinin b2 receptor antagonist which has increased usage of hereditary angioedema therapeutics market share. The global market for hereditary angioedema therapeutics is expanding as a result of factors including the increasing prevalence of hereditary angioedema, advancements in treatment options, and increasing healthcare expenditure.

Market Dynamics

Advancements in Treatment to Drive the Growth of the Hereditary Angioedema Therapeutics Market

Patients with hereditary angioedema have benefitted immensely from significant advances in therapy options, including the development of targeted therapies, gene therapies, and innovative drug delivery methods. For instance, a study published by American College of Allergy, Asthma, and Immunology in 2022 states that, the CRISPR genome editing candidate NTLA-2002 is being developed for hereditary angioedema (HAE) and is a one-time, systemically delivered treatment.

It is intended to disrupt the KLKB1 gene in liver cells, so decreasing the production of a particular protein known as kallikrein, whose unchecked activity is to blame for the recurrent, crippling, and perhaps deadly swelling events that happen in people with HAE. Thereby, the advancements in treatment will drive the market over the forecast period.

Growing Awareness is the Major Driver in the Global Hereditary Angioedema Therapeutics Market

Healthcare practitioners are becoming more knowledgeable about hereditary angioedema, its signs and symptoms, and the potential treatments. The market is growing because of increased awareness due to increased diagnosis rates, proper referrals, and efficient condition care. Furthermore, several steps taken by governments of different countries is creating awareness about these disorder.

For instance, UK Parliament celebrated hereditary angioedema (HAE) day on Tuesday 16 May 2023. Moreover, the Parliament House also supports the ambitious target of preventing swelling episodes or attacks in HAE patients. It enthusiastically supports the pledges made in the Rare Disease Framework to enhance the health of communities afflicted by rare diseases.

The House strongly urges decision-makers to acknowledge the necessity of raising clinical awareness of rare diseases, giving quality-of-life considerations a top priority in treatment recommendations, improving shared decision-making processes, and ensuring that people with affected conditions have better access to psychological support. Thus, increasing awareness about the disorder will drive the market over the forecast period.

Side Effects of Therapies will Hamper the Growth of the Market.

The side effects and safety issues of some hereditary angioedema treatments may have an adverse influence on patient compliance and restrain the market growth. For instance, using androgens prophylactically for a prolonged period of time can have unfavorable effects such as liver toxicity and virilization. Considering these factors, the side effects associated with treatment can limit the hereditary angioedema therapeutics market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has the potential to have an influence on the global market for hereditary angioedema treatments. Possible consequences include supply chain disruptions, limited access to healthcare and treatment in affected areas, economic ramifications on healthcare budgets, and a potential delay in research and development efforts. It is critical to keep a close watch on the situation in order to comprehend the market's specific consequences.

Segment Analysis

The global hereditary angioedema therapeutics market is segmented based on drug class, treatment type, route of administration, and region.

The On-Demand Segment Accounts for 53.2% of Market Share Owing to Ease of Access.

The on-demand segment is projected to dominate the global hereditary angioedema therapies market. On-demand treatments are preferred for their quick alleviation and focused intervention because they include giving drugs during acute bouts to reduce symptoms. They offer flexible treatment options for patients with rare or less severe forms of hereditary angioedema. The dominance of this market has also been aided by developments in on-demand therapies, such as the development of safer and more potent drugs.

Recombinant human C1-INH (rhC1-INH), Icatibant, a bradykinin B2-receptor antagonist, and Ecallantide, a kallikrein inhibitor (only available in the US; see FDA-approved drugs for on-demand therapy of HAE attacks), are all available intravenously.

According to research presented at the American Academy of Allergy, Asthma & Immunology's annual meeting, using sebetralstat therapy on demand has been proven to significantly reduce the symptoms and intensity of hereditary angioedema attacks. When compared to a placebo, sebetralstat showed a notable decrease in the total number of hereditary angioedema attacks and the intensity of symptoms. Notably, during acute attacks, the alleviation offered by sebetralstat was noticed within the first 30 to 60 minutes of treatment.

Geographical Analysis

North America Accounted for Approximately 39.7% of the Market Share Owing to the Increasing Prevalence of Hereditary Angioedema

North America dominates the global hereditary angioedema therapeutics market because of factors such as a higher prevalence of hereditary angioedema, greater awareness, early diagnosis, and well-established healthcare infrastructure. The region has a huge patient pool and favorable reimbursement regulations, which encourage the market's growth.

According to BioNews, Inc 2022 article, a survey of American doctors revealed that between May 2019 and April 2020, there were between 1,230 and 1,331 cases of hereditary angioedema with normal C1 inhibitors (HAE-nl-C1INH) in the country. Moreover according to Lippincott journal an article published in 2022, an estimated prevalence of HAE is approximately 1 in 50,000 people, which translates to roughly 6,000 patients with HAE in the US. Therefore, the growing prevalence of hereditary angioedema in North America to dominate the market over the forecast period.

Competitive Landscape

The major global players in the hereditary angioedema therapeutics market include: BioCryst Pharmaceuticals, Inc, CSL Behring LLC, Takeda Pharmaceutical Company, Pharming Healthcare, Inc, Sanofi, Attune Pharmaceuticals, Inc, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, and Advanced Technology & Industrial Co., Ltd, among others.

Why Purchase the Report?

• To visualize the global hereditary angioedema therapeutics market segmentation based on drug class, treatment type, route of administration, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hereditary angioedema therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as Excel consisting of key products of all the major players.

The global hereditary angioedema therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies